Topics

FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

18:32 EDT 29 Apr 2019 | OncLive

A supplemental new drug application has been submitted to the FDA for the approval of apalutamide (Erleada) for use as a treatment of patients with metastatic castration-sensitive prostate cancer.

Original Article: FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approval Sought for Apalutamide in Metastatic Castration-Sensitive Prostate Cancer"

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...